UID:
almafu_9960072256102883
Format:
1 online resource (581 p.)
ISBN:
1-281-01065-0
,
9786611010652
,
0-08-049338-6
Series Statement:
Advances in protein chemistry ; 56
Content:
Strategies to reduce medical uncertainty and build evidence have become critical to the advancement of medical knowledge and modern medical practice. As new techniques and strategies have arisen, so has the need for a current reference work. Drug Discovery and Design examines the latest research in the development of these new strategies. Some of the topics covered include angiotensin converting enzyme inhibitors, HIV protease inhibitors, PPAR agonists for diabetes, and glucan synthase antifungal agents.
Note:
Description based upon print version of record.
,
Front Cover; Drug Discovery and Design; Copyright Page; CONTENTS; PREFACE; Chapter 1. ""Natural History" Clinical Trials: An Enduring Contribution to Modern Medical Practice; I. Introduction; II. Role of the Pharmaceutical Industry in Clinical Trials; III. Use of "Natural History" RCTs to Validate the Cholesterol Hypothesis and Support Changes in the Management of Other Conditions; IV. Development of a New Chemical Entity; V. "Natural History" RCTs: Some Considerations; VI. Patient Safety; VII. Clinical Trials and the Practice of Medicine in the Age of Genomics; References
,
Chapter 2. Angiotensin-Converting Enzyme InhibitorsI. Introduction; II. Peptide Inhibitors; III. Captopril; IV. Enalapril; V. Lisinopril; VI. Fosinopril; VII. Clinically Available ACE Inhibitors; VIII. Contribution of ACE Inhibitors to the Growth of Physiological and Pathophysiological Knowledge; IX. Biological Advances in the Knowledge of ACE That Evolved in Parallel with the Drug Development Process; X. Clinical Development Process of ACE Inhibitors in Hypertension; XI. Benefits of ACE Inhibition Beyond the Fall in Blood Pressure; XII. ACE Inhibitors and Congestive Heart Failure.
,
XIII. ACE Inhibitors and Myocardial InfarctionXIV. ACE Inhibitors, Coronary Heart Disease, and Atherosis; XV. ACE Inhibitors and Prevention of Restenosis; XVI. ACE Inhibitors and Renal Insufficiency; XVII. The Fallacy of the Concepts of Normotension and Hypertension and the Cardiovascular Protective Effects of ACE Inhibitors; XVIII. Surrogate End Points in Clinical Trials of ACE Inhibition: Are We Being Misled?; XIX. Conclusion; References; Chapter 3. HMG-CoA Reductase Inhibitors; I. Background and History; II. Effects of Lipoproteins
,
III. Mechanisms of the Cholesterol-Lowering Effects of Reductase InhibitorsIV. Combination Therapy; V. Safety and Tolerability; VI. Outcome Studies; VII. Mechanisms of the Reduction in Coronary Morbidity and Mortality; VIII. Safety of HMG-CoA Reductase Inhibitors in the Megatrials; IX. Future Directions; References; Chapter 4. Cyclooxygenase-2 Inhibitors; I. Introduction; II. Background; III. Assays for Cyclooxygenase-2 Selective Inhibitors; IV. Selectivity of Cyclooxygenase Inhibitors; V. Enzymology/Medicinal Chemistry; VI. Clinical Development of Cyclooxygenase-2 Inhibitors
,
VII. Future DirectionsVIII. Conclusions; References; Chapter 5. 5a-Reductase Inhibitors; I. Introduction; II. Identification and Characterization of 5a-Reductase; III. Development of 5a-Reductase Inhibitors; IV. Clinical Studies in Men with Androgenic Disorders; V. Clinical Studies in Women with Androgenic Disorders; VI. Other 5a-Reductase Inhibitors; VII. Conclusion; References; Chapter 6. Peroxisome Proliferator-Activated Receptor (PPAR)? Agonists for Diabetes; I. Introduction; II. Mechanism of Action of Peroxisome Proliferator-Activated Receptor (PPAR)? Agonists
,
III. Clinical Experience with PPAR? Agonists
,
English
Additional Edition:
ISBN 0-12-034256-1
Language:
English
Bookmarklink
